SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)
ACAD 25.03+0.8%12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw12/18/2007 5:05:59 AM
  Read Replies (1) of 588
 
citi:
ACADIA Pharmaceuticals Inc (ACAD)
Acadia Provides Update; ACP Phase II data in 2Q08

? ACP-104 Phase II trial in schizophrenia completes enrollment with top-line
results expected in 2Q:08. Study design: 240 patients, 3 arms (100 mg bid,
200 mg bid, and placebo); 6-week assessment for response; weekly blood
monitoring; primary endpoint of PANSS from baseline (LOCF). The soonerthan-
expected enrollment indicates the unmet need of a drug like clozapine
but without the side effects in schizophrenia.

? Pimavanserin for Parkinson’s Psychosis — No change in timeline, topline
results still expected 2009. Nearly all U.S. sites enrolling, International sites to
begin enrollment shortly. High unmet medical need exists as Seroquel is most
commonly used agent but has failed two trials.

? Preclinical data suggests Pimavanserin works with other atypical agents.
Importantly, Dr. Meltzer believes that all atypicals can have their effective dose
reduced by 2/3 with Pimavanserin, specifically that Zyprexa could be used at
3-4mg based on preclinical imaging studies. If this can be demonstrated in
clinical trials, it would provide significant value to Pimavanserin franchise.

? Focus on Cognition in Schizophrenia—Preclinical data suggests both
Pimavanserin and ACP-104 may enhance cognition, whereas most approved
atypical drugs demonstrate a neutral to negative effect on cognition.

? Conclusion(s)—We are incrementally more positive on ACAD but we are waiting
for a partnership or ACP-104 phase IIb data to reassess. We maintain Hold.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News